IQWiG in dialogue
Uncertainty in benefit assessments
Since the new Version 4.0 of the General Methods in 2011, IQWiG has been using the three terms "proof", "indication" and "hint" to formulate conclusions on the benefit or harm of medical interventions. The use of these terms depends on the certainty of results of the underlying studies. "Proof” of a benefit can only be confirmed in cases with high certainty of results. "Indication” refers to the weaker, while” hint” refers to the weakest level of certainty of results within the three categories. If, for instance, studies use surrogate endpoints or indirect comparisons, the uncertainty of study results increases.
In this year's "IQWiG in Dialogue”, for discussion with experts the Institute presents its approach to drawing conclusions on benefit in cases of increased uncertainty.
- Introduction Dr. Ralf Bender
- Why do surrogate endpoints lead to increased uncertainty? Dr. Christoph Schürmann
- Certainty of conclusions in the assessment of non-drug and drug interventions? practical examples Dr. Stefanie Thomas
- Network meta-analyses and indirect comparisons: increased (un)certainty? Prof. Dr. Peter Jüni (University of Bern)
- Test directives according to §137e Social Code Book V: "Proof", "indication" or "hint" - How much certainty of results is necessary to attest that a method has "potential"? PD Dr. Matthias Perleth (Federal Joint Committee, Berlin)
- Is there an added benefit by introducing the category "hint? to describe certainty of results? Dr. Carsten Schwenke (SCO:SSiS, Berlin)